Trial | NCT02004197  Report issue

Title

Quadruple and Phytomedicine-based Therapies in H. Pylori Infection
Phytomedicine-based and Quadruple Therapies in Helicobacter Pylori Infection. A Comparative Randomized Trial

  • Phase

    Phase 2/Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    176
Helicobacter pylori is strongly associated to the development of gastrointestinal disorders. Emerging antibiotic resistance and poor patient compliance of modern therapies has resulted in significant eradication failure. Clinical trial was conducted to see the efficacy of current quadruple and phytomedicine-based therapies for the eradication of H. pylori infection and relief in its associated symptoms in Pakistan.
Study Started
Jan 31
2010
Primary Completion
Sep 30
2012
Study Completion
Jan 31
2013
Last Update
Dec 09
2013
Estimate

Drug Quadruple Allopathic therapy

  • Other names: Omeprazol, Amoxicillin, Metronodazole, TRITEC (ranitidine bismuth citrate)

Drug Pylorex plus

Quadruple therapy Active Comparator

Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)

Pylorex plus Experimental

Pylorex plus consisting of medicinal plants.

Criteria 

Inclusion Criteria:

The patients suffering from H. pylori infection
Patients having no previous record of treatment against H. pylori infection
Patients living in Karachi, Rawalpindi and Bahawalpur
Patients having no pathological complications on routine examination
All socioeconomic classes were included in the study
Male and female patients between 15 to 45 years of age

Exclusion Criteria:

there was peptic ulceration, gastrointestinal bleeding or gastric carcinoma
if history of use of antibiotics, proton-pump inhibitors or bismuth compound in the last one month before test
any patient found to be allergic or intolerant to therapeutic regimens
they failed to report for follow-up
No Results Posted